Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase  by Okamoto, Koji et al.
FEBS Letters 583 (2009) 2710–2714journal homepage: www.FEBSLetters .orgMdmx enhances p53 ubiquitination by altering the substrate preference
of the Mdm2 ubiquitin ligase
Koji Okamoto a,b,c, Yoichi Taya b,c,1, Hitoshi Nakagama a,*
aNational Cancer Center Research Institute, Early Oncogenesis Research Project, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
bNational Cancer Center Research Institute, Radiobiology Division, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
c SORST, Japan Science and Technology Corporation, Japan
a r t i c l e i n f o a b s t r a c tArticle history:
Received 11 May 2009
Revised 26 June 2009
Accepted 13 July 2009
Available online 18 July 2009
Edited by Noboru Mizushima
Keywords:
Mdmx
Mdm2
p53
Ubiquitination0014-5793/$36.00  2009 Federation of European Bio
doi:10.1016/j.febslet.2009.07.021
* Corresponding author.
E-mail address: hnakagam@ncc.go.jp (H. Nakagam
1 Present address: Cancer Science Institute of Sing
Singapore, Singapore 117456, Singapore.mdm2 andmdmx oncogenes play essential yet non-redundant roles in synergistic inactivation of the
tumor suppressor, p53. While Mdm2 inhibits p53 activity mainly by augmenting its ubiquitination,
the functional role of Mdmx on p53 ubiquitination remains obscure. In transfected H1299 cells,
Mdmx augmented Mdm2-mediated ubiquitination of p53. In in vitro ubiquitination assays, the
Mdmx/Mdm2 heteromeric complex, in comparison to the Mdm2 homomer, showed enhanced
ubiquitinase activity toward p53 and the reduced auto-ubiquitination of Mdm2. Alteration of the
substrate speciﬁcity via binding to Mdmx may contribute to efﬁcient ubiquitination and inactiva-
tion of p53 by Mdm2.
Structured summary:
MINT-7219995: P53 (uniprotkb:P04637) physically interacts (MI:0914) with Ubiquitin (uniprotkb:
P62988) by anti bait coimmunoprecipitation (MI:0006)
MINT-7220023: Ubiquitin (uniprotkb:P62988) physically interacts (MI:0914) with P53 (uniprotkb:
P04637) by pull down (MI:0096)
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The p53 tumor suppressor protein plays a central role in pre-
venting tumorigenesis. p53 functions as a sequence-speciﬁc tran-
scriptional factor [1,2], and activated p53 exerts its function as a
tumor suppressor by inducing numerous target genes [3–6]. In
most cancer cells, its activity is lost via alteration of its gene or
via other cellular events that inactivate p53 [7–9].
Mdm2 and Mdmx function as two major players in the suppres-
sion of p53 activity [10]. Accumulating reports indicate that the
major function of Mdm2 in suppressing p53 is attributed to
Mdm2-dependent p53 ubiquitination, which triggers proteasomal
degradation or nuclear export of p53 [11], although it has been re-
ported that Mdm2 inactivates p53 by other mechanisms [12–15].
Mdm2 possesses a RING ﬁnger domain, a protein–protein interac-
tion motif that is found in many eukaryotic proteins and often pos-
sesses E3 ubiquitin ligase activity [16]. Indeed, Mdm2 functions aschemical Societies. Published by E
a).
apore, National University ofan E3 ubiquitin ligase, and the RING domain of Mdm2 is essential
for its ubiquitin ligase activity toward p53 and Mdm2 itself [17–
19].
Mdmx shares an extensive structural homology with Mdm2,
and forms a heterodimer complex with Mdm2 through their RING
ﬁnger domains [20,21], yet Mdmx in itself lacks the robust activity
of an E3 ubiquitin ligase [22]. Thus, both genetic and biochemical
evidence indicates that Mdmx and Mdm2 perform distinct yet
co-operative functions in p53 inactivation.
Recent reports suggest that Mdmx may inactivate p53 by aug-
menting Mdm2-mediated ubiquitination of p53 [23–25]. However,
precise mechanism by which Mdmx stimulates p53 ubiquitination
by Mdm2 is not yet known.
In this paper, we demonstrated that wild-type Mdmx is capable
of enhancing Mdm2-mediated p53 ubiquitination in vivo. Further,
the in vitro study using puriﬁed Mdm2 or the Mdm2/Mdmx
complex revealed that, when complexed with Mdmx, the extent
of p53 ubiquitination by Mdm2 was enhanced while poly-ubiquiti-
nation of Mdm2 was signiﬁcantly decreased. We propose that the
effect of Mdmx on the preference of the substrate of the Mdm2
ubiquitin ligase plays an important role in effective ubiquitination
of p53.lsevier B.V. All rights reserved.
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2.1. DNA transfection
In DNA transfection experiments using H1299 cells, 2 lg of DNA
and 4 ll of Lipofectamine 2000 reagent (Invitrogen) were
introduced per 2.0  105 cells according to manufacturer’s proto-
col. Cells were then incubated for 20 h before harvesting.
2.2. In vivo ubiquitination assay
For detection of p53 conjugated with endogenous ubiquitin,
in vivo ubiquitination assays were performed as previously de-
scribed [26] with some modiﬁcations. Transfected H1299 cells
were lysed in SDS lysis buffer (50 mM Tris, pH 7.5, 100 mM NaCl,
1% SDS) supplemented with 1 mM DTT and protease inhibitor
cocktail (PI) [27], boiled for 10 min, and diluted with 4 volumes
of dilution buffer (50 mM Tris, pH 7.5, 100 mM NaCl, 1.25% Triton
X-100) supplemented with DTT and PI. After sonication of the ly-
sates, p53 was immunoprecipitated with anti-p53 antibody (DO-
1). Subsequently the immunoprecipitates were washed three times
with 200-NP buffer [27], and analyzed by Western blotting with
DO-1 and anti-ubiquitin antibody (FK2, MBL).
For detection of p53 conjugated with transfected (His)6-ubiqui-
tin, transfected H1299 cells were lysed in urea lysis buffer
(100 mM NaH2PO4, 10 mM Tris–HCl, pH 8.0, 500 mM NaCl, 10%
glycerol, 0.1% Triton X-100, 10 mM imidazole) supplemented with
10 mM b-mercaptoethanol, PI, 5 mM Iodoacetamide, and 1 mg/ml
NEM. Proteins conjugated with His-tagged ubiquitin were puriﬁed
as described before [28], and analyzed by Western blot analysis.
2.3. Protein expression and puriﬁcation
Flag-tagged Human Mdm2 (Flag-Mdm2) or Human Mdmx RNA
was transcribed from the corresponding cDNA using the Wheat
Germ Expression Kit (Cell Free Science, Japan). Subsequently, the
Flag-Mdm2 RNA alone or in combination with an excess amount
of the Mdmx RNA was used for in vitro translation with wheat
germ lysate (Cell Free Science) according to the manufacturer’sFig. 1. Mdmx cooperates with Mdm2 to induce p53 ubiquitination. HA-p53 (0.15 mg) a
mutant were transfected into H1299 cells in the presence of 0.2 mg of Myc-Mdm2. Th
(Stratagene). Twenty hours after transfection, lysates prepared under denaturing con
immunoprecipitates were then used for Western blot analyses with DO-1 (left panel, and
Amounts of immunoprecipitates used for Western were normalized such that an equalinstructions. Flag-Mdm2 or the Flag-Mdm2/Mdmx complex was
then puriﬁed on agarose conjugated with anti-Flag antibody.
2.4. In vitro ubiquitination assay
In vitro ubiquitination assays were performed as previously de-
scribed with some modiﬁcations [29]. Approximately 100 ng of
Flag-Mdm2 or the Flag-Mdm2/Mdmx complex were mixed with
the following puriﬁed components; 8 ng of GST-p53, 10 ng of E1
(Boston Biochem), 80 ng of E2 (UbcH5b, Boston Biochem), 3 lg of
His-ubiquitin (Calbiochem), or methylated ubiquitin (Boston Bio-
chem). In experiments shown in Fig. 4D, 125I-ubiquitin (Perkin–El-
mer) was included in the reaction mixture. These components
were incubated in a reaction buffer (40 mM Tris–HCl, pH 7.5,
5 mMMgCl2, 10 mM NaCl) in the presence of 2 mM Mg–ATP at
37 C for the indicated times. After the reactions were terminated
by adding SDS sample buffer, ubiquitinated proteinswere separated
in SDS–PAGE gels and detected by Western blot analyses or
autoradiography.
3. Results
3.1. Wild-type Mdmx was capable of enhancing p53 ubiquitination in
the presence of Mdm2 in vivo
Recently, we demonstrated that the non-phosphorylatable, ac-
tive form of Mdmx augments p53 ubiquitination mediated by
wild-type Mdm2 in transfected H1299 cells [30]. In order to deter-
mine whether wild-type Mdmx cooperates with Mdm2 to induce
ubiquitination of p53 as well, wild-type Mdmx (Mdmx-wt) or
the non-phosphorylated form of Mdmx (Mdmx-3A) was transfec-
ted together with Mdm2 into H1299 cells, and conjugation of
p53 with endogenous ubiquitin was examined by Western blot
analyses (Fig. 1). As expected from previous observation [30],
Mdmx-3A, which is resistant to Mdm2-mediated ubiquitination
and degradation, was expressed at higher levels than wild-type
Mdmx (Fig. 1, lanes 2 and 3). p53 ubiquitination induced by
Mdm2 was enhanced in the presence of co-transfected wild-type
Mdmx (Fig. 1, lanes 5 and 8), indicating that wild-type Mdmx is
capable of stimulating Mdm2-mediated ubiquitination of p53,nd either 0.4 mg of the control vector, wild-type Flag-Mdmx, or the Flag-Mdmx-3A
e total amount of transfected DNA was adjusted to 2 lg with pBluescript plasmid
ditions were used for immunoprecipitaiton with anti-p53 (DO-1) antibody. The
right bottom panel for low exposure) and with anti-ubiquitin antibody (right panel).
amount of non-ubiquitinated p53 was loaded in each lane.
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the non-phosphorylatable mutant (Fig. 1, lanes 6 and 9).
3.2. Mutation at the C-terminal ubiquitinated lysines largely abolished
p53 ubiquitination by Mdmx
It has been documented that Mdm2 ubiquitinates p53 at the six
C-terminal lysines, the integrity of which are required for its nucle-
ar export [31,32]. We created a mutant p53 in which all six lysines
at the C-terminal domain (Fig. S1) were substituted by arginine
(p53-K6R), and introduced wild-type p53 or the K6R mutant into
H1299 cells together with Mdm2 in the presence or absence of
Mdmx-3A. Examination of p53 ubiquitination in vivo revealed that
the K6R mutation eliminates a majority of p53 ubiquitination en-
hanced by Mdmx (Fig. S2), indicating the six lysines were major
sites for Mdmx-dependent ubiquitination.
3.3. Association of Mdmx with Mdm2 augments the ability of Mdm2 to
ubiquitinate p53 and inhibits poly-ubiquitination of Mdm2 in vitro
In order to determine whether Mdmx enhances Mdm2-depen-
dent ubiquitination of p53 via direct association with Mdm2, we
next performed in vitro ubiquitination assays using puriﬁed re-
combinant proteins of Mdm2 or an Mdm2/Mdmx complex (seeFig. 2. Association of Mdmx with Mdm2 augments the activity of Mdm2 to ubiquitinate p
the Mdm2/Mdmx complex. Flag-tagged Mdm2 was translated alone, or co-translated with
puriﬁed proteins were separated by10% SDS–PAGE, and detected by silver staining (right
antibody (D-19) (left panel). (B) In vitro ubiquitination assays were performed with pu
indicated times, and the extent of p53 ubiquitination and Mdm2 auto-ubiquitination wa
The position of non-ubiquitinated substrates is designated by arrows. (C) In vitro ubiquit
were terminated after 30 min. Ubiquitination of Mdmx, p53, and Mdm2 was evaluatedSection 2). Silver staining of the puriﬁed proteins indicated that
the co-puriﬁed Mdmx formed a complex with Mdm2 at approxi-
mately a 1:1 molar ratio (Fig. 2A, right panel).
In order to determine the effect of the association with Mdmx
on the activity of E3 ubiquitin ligase of Mdm2, homomeric
Mdm2 or the Mdmx/Mdm2 complex was incubated with E1, E2
(UbcH5b), GST-p53, and ubiquitin, and time-course analyses of
the ubiquitination of p53 and auto-ubiquitination of Mdm2 were
simultaneously performed. The complex formation of Mdm2 with
Mdmx-3A or with wild-type Mdmx resulted in an increase of p53
ubiquitination (Fig. 2B and C). In contrast, the Mdmx/Mdm2 com-
plex showed a marked decrease in poly-ubiquitinated forms of
Mdm2 in comparison to homomeric Mdm2 (Fig. 2B and C), indicat-
ing that the association with Mdmx-3A augments Mdm2-depen-
dent p53 ubiquitination while it inhibits poly-ubiquitination of
Mdm2.3.4. Mdmx inhibits ubiquitination of the Mdm2-containing enzymatic
complex
In order to conﬁrm that Mdmx inhibits auto-ubiquitination of
Mdm2, in vitro ubiquitination assays of the Mdm2 homomer or
the Mdm2/Mdmx complex were performed in the presence of53 and inhibits auto-ubiquitination of Mdm2 in vitro. (A) Puriﬁcation of Mdm2 and
Mdmx-3A or wild-type Mdmx in wheat germ lysates, as described in Section 2. The
panel), or by Western blotting analyses with anti-Flag antibody (M2) or anti-Mdmx
riﬁed Mdm2 or Mdmx-3A/Mdm2. Ubiquitination reactions were terminated at the
s evaluated by Western blot analyses with anti-Flag antibody or anti-p53 antibody.
ination assays were performed as described in (B), and the ubiquitination reactions
by Western blot analyses.
Fig. 3. In vitro ubiquitination reaction was performed as described in Fig. 2C, except that 125I-labeled ubiquitin was included in the reaction. (left panel) Ubiquitinated Mdm2
or Mdm2/Mdmx was separated by 10% SDS–PAGE, and detected by autoradiography. Note that the ladder represents a mixture of ubiqutination of Mdm2 and Mdmx in lanes
7–12 (left panel). Levels of the ubiquitination were quantiﬁed and relative levels of ubiquitination were plotted (right panel).
K. Okamoto et al. / FEBS Letters 583 (2009) 2710–2714 2713125I-labeled ubiquitin. Quantiﬁcation of ubiquitin attached to the
enzymatic complexes demonstrated that the auto-ubiquitination
of the Mdm2 was indeed hindered by the complex formation with
either wild-type Mdmx or Mdmx-3A (Fig. 3). Thus, the complex
formation of Mdm2 with Mdmx affects the preference for the sub-
strate of the Mdm2 ubiquitin ligase.
3.5. Mdmx stimulates Mdm2-dependent mono-ubiquitination of p53
It has been documented that poly-ubiquitination of p53 induces
its degradation, while its mono-ubiquitnation stimulates nuclear
export of p53 [33]. Because Mdmx does not signiﬁcantly contribute
to p53 degradation [34], we attempted to determine whether
Mdmx stimulates mono-ubiquitination of p53 rather than its
poly-ubiquitination. Mdm2 and p53 were introduced into H1299
cells together with His-Ub-K7R, (His)6-tagged mutant ubiquitinFig. 4. Mdmx-3A or the control vector was transfected into H1299 cells together
with Myc-Mdm2, HA-p53 and the indicated (His)6-tagged ubiquitin K7R mutant.
Twenty hours after transfection, cells were lysed with a buffer containing 6 M urea,
and normalized lysates that contain equal amounts of non-ubiquitinated p53 were
used to purify His-tagged ubiquitin on Ni-NTA agarose (QIAGEN). Ubiquitinated p53
was detected by Western blot analysis with anti-p53 antibody (DO-1).which is not capable of forming a ladder of poly-ubiquitination
due to arginine substitution in all seven lysine residues [29]. Sub-
sequently, His-Ub-K7R was puriﬁed from lysates that were pre-
pared from transfected cells, and p53 conjugated with His-Ub-
7KR was detected by Western blot analyses with anti-p53 anti-
body. The introduction of wild-type Mdmx augmented mono-
ubiquitination of p53 (Fig. 4, lane 2), and the Mdmx-3A mutation
further enhanced the p53 mono-ubiquitination (Fig. 4, lane 3).
In order to determine whether Mdmx stimulates Mdm2-depen-
dent mono-ubiquitination of p53 in vitro as well as in vivo, meth-
ylated ubiquitin was used instead of wild-type ubiquitin in in vitro
ubiquitination assays. Indeed, the Mdmx/Mdm2 complex showed a
stronger activity for p53 mono-ubiquitination than the homomeric
Mdm2 (Fig. S3). Thus, the formation of a complex with Mdmx aug-
ments the activity of Mdm2 to mono-ubiquitinate p53.
4. Discussion
In this report, we demonstrated that wild-type Mdmx as well as
its non-phosphorylatable mutant cooperates with Mdm2 to stimu-
late ubiquitination of p53 both in vivo and in vitro. In agreement
with our observation, it was reported that Mdmx enhances the
activity of Mdm2 as a ubiquitin ligase in vitro [35]. Mdmx comple-
ments the catalytic function of mutant Mdm2 proteins that are
deﬁcient in the enzymatic activity as a ubiquitin ligase [23–25]
and Mdmx/Mdm2 hetero-RING complexes exhibit a greater E3 li-
gase activity than homomeric Mdm2 [36]. Such effects of Mdmx
on Mdm2 should enhance Mdm2-dependent ubiquitination of
p53, consistent with the role of Mdmx as an inhibitor of p53.
It was previously reported that Mdmx augments not only auto-
ubiquitination of Mdm2 but also the ubiquitin ligase activity of
Mdm2 toward p53 [35] in in vitro assays. However, auto-ubiquiti-
nation of the Mdm2 ubiquitin ligase negatively affects its activity
because poly-ubiquitinated Mdm2 is targeted for proteasome-
mediated degradation. Therefore, enhanced ubiquitinase activity
of Mdm2 by Mdmxmay not be translated into efﬁcient stimulation
of p53 ubiquitination if the association of Mdmx to Mdm2 simul-
taneously leads to stimulation of self-destruction of Mdm2. Our
2714 K. Okamoto et al. / FEBS Letters 583 (2009) 2710–2714observation that Mdmx inhibits poly-ubiquitination of Mdm2
while it stimulates p53 ubiquitination may attribute to a mecha-
nism by which Mdmx stimulates Mdm2-dependent p53 ubiquiti-
nation without enhanced destruction of Mdm2, thus providing
the molecular basis of how Mdmx cooperates with Mdm2 to inhi-
bit p53 activity.
Recently Linke et al. reported the crystal structure of the hetero-
dimer of Mdmx/Mdm2 RING domain, and proposed a model that
favors transfer of ubiquitin to Mdmx that does not interact with
E2 [37]. This can explain why Mdm2 is not extensively ubiquitinat-
ed in the Mdmx/Mdm2 heteromeric complex, thus providing
mechanistic basis for reduced ubiquitination of Mdm2 in the
Mdmx/Mdm2 complex (Fig. 2). It is noteworthy that, in in vitro
ubiquitination assays, the levels of Mdm2 ubiquitination in the
homomeric Mdm2 are higher than combined levels of ubiquitina-
tion of Mdm2 and Mdmx in the heteromeric complex (Fig. 3).
Therefore, it is likely that Mdmx is relatively resistant to ubiquiti-
nation by bound Mdm2, unless Mdmx undergoes speciﬁc modiﬁ-
cation such as phosphorylation [27].
It is not clear at this moment how Mdmx stimulates Mdm2-
mediated ubiquitination of p53. Mdm2 bound to Mdmx may posi-
tion its catalytic domain more closer to the C-terminal domain of
p53 than homomeric Mdm2, resulting in enhanced p53 ubiquitina-
tion. Alternatively, Mdm2 or Mdmx may compete with p53 as a
substrate for Mdm2, and relative resistance of Mdmx against ubiq-
uitination by bound Mdm2 may translate into facilitated p53 ubiq-
uitination. Presumably, these two possibilities are not mutually
exclusive, and combined effects of Mdmx on Mdm2-mediated
ubiquitination may serve to stimulate ubiquitination and inactiva-
tion of p53.
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